• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Coya Therapeutics Inc.

    5/16/25 5:05:18 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $COYA alert in real time by email
    DEFA14A 1 d874014ddefa14a.htm DEFA14A DEFA14A
     
     

    United States

    Securities and Exchange Commission

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    COYA THERAPEUTICS, INC.

    (Name of Registrant as Specified in its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

     

     2025 Stockholder Meeting Notice    LOGO

    Important Notice Regarding the Availability of Proxy Materials for the

    Coya Therapeutics, Inc. Stockholder Meeting to be Held on June 26, 2025.

    Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

    This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Proxy Statement; Annual Report on Form 10-K for the Year Ended December 31, 2024 are available at:

     

    www.envisionreports.com/COYA

     

     

    LOGO

     

    Easy Online Access – View your proxy materials and vote.

     

      Step 1:    Go to www.envisionreports.com/COYA.
      Step 2:    Click on Cast Your Vote or Request Materials.
      Step 3:    Follow the instructions on the screen to log in.
      Step 4:    Make your selections as instructed on each screen for your delivery preferences.
      Step 5:    Vote your shares.

    When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

     

     

     

    LOGO   Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before May 26, 2025 to facilitate timely delivery.

     

    ⬛   2NOT   COY   LOGO

    045JMB


     
     2025 Stockholder Meeting Notice

    Coya Therapeutics, Inc. Annual Meeting of Stockholders will be held on June 26, 2025, virtually at meetnow.global/MJYXQX7, at 12:00 p.m. Central Time.

    Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations.

    The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposal 2:

     

      1.

    Election of Directors:

    01 - Howard Berman, Ph.D.

    02 - Arun Swaminathan, Ph.D.

    03 - Ann Lee, Ph.D.

      2.

    Ratify the appointment of Weaver and Tidwell, L.L.P. as the Company’s independent public accounting firm for the year ending December 31, 2025

    PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote at the meeting, please bring this notice with you.

     

     

     

     

    LOGO   

    Here’s how to order a copy of the proxy materials and select delivery preferences:

     

    Current and future delivery requests can be submitted using the options below.

     

    If you request an email copy, you will receive an email with a link to the current meeting materials.

     

    PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials.

     

    –   Internet – Go to www.envisionreports.com/COYA. Click Cast Your Vote or Request Materials.

     

    –   Phone – Call us free of charge at 1-866-641-4276.

     

    –   Email – Send an email to [email protected] with “Proxy Materials Coya Therapeutics, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials.

     

    To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by May 26, 2025.

    Get the next $COYA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COYA

    DatePrice TargetRatingAnalyst
    7/9/2025$16.00Buy
    Lake Street
    12/4/2024$15.00Buy
    D. Boral Capital
    More analyst ratings

    $COYA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Snyder David S bought $12,934 worth of shares (1,800 units at $7.19), increasing direct ownership by 26% to 8,800 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/14/24 6:08:32 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Swaminathan Arun bought $36,797 worth of shares (5,000 units at $7.36), increasing direct ownership by 100% to 10,000 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/13/24 4:05:16 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Grossman Fred bought $19,973 worth of shares (2,710 units at $7.37) (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    11/12/24 6:03:34 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

    The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at clinical sites in the United States and Canada Dosing of ALS patients has commenced in the ALSTARS Trial and signifies a key milestone for the Company. COYA 302, a combination of proprietary low-dose IL-2 and CTLA-4 Ig, is designed to enhance the number and function of regulatory T cells while suppressing the pro-inflammatory myeloid activity that drives ALS progression. COYA will receive a $4.2 million milestone payment from its strategic partner, Dr. Reddy's Laboratories (DR

    12/9/25 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials Conferences

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative disorders, announces the company's management team will participate in two upcoming conferences. 8th Annual Evercore Healthcare Conference Date: December 2, 2025 Time: 8:45-9:05 am ET Format: Fireside Chat Participant: Dr. Arun Swaminathan, Ph.D., Chief Executive Officer Location: Miami, FL Webcast: https://wsw.com/webcast/evercore52/coya/2359192 Coya's management team will be available for one-on-one meetings during the Everc

    11/25/25 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

    ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. "We are delighted to welcome Howard to ReAlta at a pivotal moment for the Company as we move towards meaningful catalysts," said Kenji Cunnion, M.D., MPH, Co-Founder, Chief Medical Officer and Board Member of ReAlta. "His proven track record in advancing innovative immunology-based therapies and creatin

    11/25/25 8:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Coya Therapeutics with a new price target

    Lake Street initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $16.00

    7/9/25 8:41:23 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    D. Boral Capital initiated coverage on Coya Therapeutics with a new price target

    D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

    12/4/24 7:30:44 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    SEC Filings

    View All

    SEC Form 10-Q filed by Coya Therapeutics Inc.

    10-Q - Coya Therapeutics, Inc. (0001835022) (Filer)

    11/12/25 8:13:44 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

    11/12/25 8:03:52 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

    8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

    10/27/25 7:36:46 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Goldstein Dov A Md exercised 17,557 shares at a strike of $1.09, increasing direct ownership by 176% to 27,557 units (SEC Form 4)

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    8/19/25 4:01:23 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Weinand Dieter

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    2/25/25 9:30:04 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Ross Wilbur L Jr

    4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

    2/25/25 9:30:03 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Leadership Updates

    Live Leadership Updates

    View All

    ReAlta Life Sciences Appoints Dr. Howard Berman as Executive Chairman

    ReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of inflammatory disorders, today announced the appointment of Howard Berman, Ph.D., as Executive Chairman of the ReAlta Life Sciences Board of Directors, effective immediately. "We are delighted to welcome Howard to ReAlta at a pivotal moment for the Company as we move towards meaningful catalysts," said Kenji Cunnion, M.D., MPH, Co-Founder, Chief Medical Officer and Board Member of ReAlta. "His proven track record in advancing innovative immunology-based therapies and creatin

    11/25/25 8:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of Directors

    Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand's profound knowledge will guide the Board as the company advances its innovative Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology and pipeline of folding interference small molecules to address a range of cha

    5/8/25 5:00:00 AM ET
    $COYA
    $REPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program

    BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) ("Atea" or "Company"), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Howard H. Berman, Ph.D. to its Board of Directors (the "Board"). Dr. Berman will serve as a non-voting observer to the Board through Atea's 2025 Annual Meeting of Stockholders when he will join the Board as a full voting member. "We are pleased to welcome Howard Berman to the Atea Board," said Jean-Pierre Sommadossi, Ph.D., Chief Executive Officer and Founder of Atea. "We look forward to benefitting from

    4/17/25 7:00:00 AM ET
    $AVIR
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Financials

    Live finance-specific insights

    View All

    Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer's Disease

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

    10/28/24 8:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics, Inc. Provides Business Update and Reports Q3 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

    11/8/23 9:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Coya Therapeutics, Inc. Provides Business Update and Reports Q2 2023 Unaudited Financial Results

    Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

    8/8/23 7:00:00 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $COYA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/12/24 3:37:54 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/4/24 1:27:32 PM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Coya Therapeutics Inc.

    SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

    11/4/24 11:42:58 AM ET
    $COYA
    Biotechnology: Pharmaceutical Preparations
    Health Care